Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01802723 · ClinicalTrials.gov registry record · Phase 2
Dose Ranging Study
A Phase 2 study, sponsored by Neothetics.
- Completed
- Registry status
- Phase 2
- Development phase
- 472
- Enrollment target
NCT01802723: Completed Phase 2 study, sponsored by Neothetics.
NCT01802723 is a Phase 2 study that has completed, run by Neothetics. The registered enrollment target is 472 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (255% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01802723, a Phase 2 study, has completed, sponsored by Neothetics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 472 participants
- Enrollment target
Study Summary
Dose Ranging Study
Primary Outcome
physical exam, vital signs, clinical assessment of injection, clinical laboratory tests, and adverse events
Interventions
- DRUG Drug: salmeterol xinafoate
- DRUG Drug: Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 472 participants |
| Start Date | 2013-02 |
| Est. Completion | 2013-10 |
| Phase | Phase 2 |
What the finished NCT01802723 record still lists
NCT01802723 is an interventional study that assigns participants to a tested intervention. The registered 472 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (255% higher).
The record links to 0 conditions, and to 2 interventions - of which Drug: salmeterol xinafoate is the first listed.
NCT01802723 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01802723 about?
NCT01802723 is a clinical study titled "Dose Ranging Study". Dose Ranging Study
What is the current status of trial NCT01802723?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 472 participants. The study started on 2013-02. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01802723?
The interventions under investigation include: Drug: salmeterol xinafoate (DRUG), Drug: Placebo (DRUG).
Who is sponsoring clinical trial NCT01802723?
This trial is sponsored by Neothetics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01802723's enrollment target sits among peer trials
472 78th of 2000 higher than 1,923 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06375083 · 472 participants · Phase 2
Computerized Cognitive Behavioral Therapies for Suicide Prevention and Depression
- NCT06947187 · 472 participants · NA
Vaccine Confidence and Infodemic in Southeast Asia's Nusantara Sociocultural Sphere
- NCT07199517 · 472 participants · NA
Catalyzing Cigarette Smoking Cessation Through Harm Reduction Sampling Among People Unmotivated to Quit
- NCT07225881 · 472 participants · NA
Eatwell Clinical Trial (R01)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia